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Abstract
Background: A general practitioner (GP)-targeted intervention aimed at improving the prescribing of appropriate
polypharmacy for older people was previously developed using a systematic, theory-based approach based on the UK
Medical Research Council’s complex intervention framework. The primary intervention component comprised a video
demonstration of a GP prescribing appropriate polypharmacy during a consultation with an older patient. The video
was delivered to GPs online and included feedback emphasising the positive outcomes of performing the behaviour.
As a complementary intervention component, patients were invited to scheduled medication review consultations
with GPs. This study aimed to test the feasibility of the intervention and study procedures (recruitment, data collection).
Methods: GPs from two general practices were given access to the video, and reception staff scheduled consultations
with older patients receiving polypharmacy (≥4 medicines). Primary feasibility study outcomes were the usability and
acceptability of the intervention to GPs. Feedback was collected from GP and patient participants using
structured questionnaires. Clinical data were also extracted from recruited patients’ medical records (baseline
and 1 month post-consultation). The feasibility of applying validated assessment of prescribing appropriateness (STOPP/
START criteria, Medication Appropriateness Index) and medication regimen complexity (Medication Regimen Complexity
Index) to these data was investigated. Data analysis was descriptive, providing an overview of participants’ feedback and
clinical assessment findings.
Results: Four GPs and ten patients were recruited across two practices. The intervention was considered usable and
acceptable by GPs. Some reservations were expressed by GPs as to whether the video truly reflected resource and time
pressures encountered in the general practice working environment. Patient feedback on the scheduled consultations
was positive. Patients welcomed the opportunity to have their medications reviewed. Due to the short time
to follow-up and a lack of detailed clinical information in patient records, it was not feasible to detect any
prescribing changes or to apply the assessment tools to patients’ clinical data.
Conclusion: The findings will help to further refine the intervention and study procedures (including time to
follow-up) which will be tested in a randomised pilot study that will inform the design of a definitive trial to
evaluate the intervention’s effectiveness.
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Background
Older people are the greatest consumers of healthcare
resources in developed countries. Given the predicted
increases in the size of the older population, the use of
medicines in this population cohort has been described
as the ‘single most important health care intervention in
the industrialised world’ [1]. The prescribing of multiple
medicines, also termed polypharmacy, is increasingly
common in older people [2, 3] and is considered to be
one of the most pressing prescribing challenges [4]. En-
suring ‘appropriate polypharmacy’ in this patient cohort,
whereby prescribing is evidence-based and reflects pa-
tients’ clinical needs, is a challenge faced by clinicians
that is of considerable clinical and economic importance
[5]. Polypharmacy is the principal contributing factor to
potentially inappropriate prescribing in older popula-
tions [6, 7] and has been associated with a range of
negative clinical consequences, including adverse drug
events (ADEs) and medication non-adherence [8]. Po-
tentially inappropriate prescribing in older people places
a substantial financial burden on health services [6, 7].
Improving appropriate polypharmacy in older people
poses challenges on a number of levels. For example, the
availability of guidelines to inform prescribing practices/
decisions for older people who commonly suffer from
more than one chronic condition (i.e. multimorbidity) is
currently lacking [9]. Prescribing guidelines typically deal
with single diseases, and when applied to complex multi-
morbid patients, they often fail to provide guidance on
how to prioritise treatment recommendations and can
act as a contributing factor for polypharmacy [10]. There
has been some progress in addressing this issue with the
recent publication of guidelines for the clinical assess-
ment and management of patients with multimorbidity
by the National Institute for Health and Care Excellence
(NICE) [11]. However, it will be some time before the
clinical impact of these guidelines is fully established,
particularly as their implementation may require some
reorganisation in the way in which care is currently
delivered [12].
Another challenge is that there are considerable
deficits in the current evidence base for interventions
that target clinical practice and aim to improve out-
comes for patients with complex clinical needs, such as
multimorbidity and polypharmacy [13, 14]. For example,
a Cochrane systematic review of interventions to im-
prove appropriate polypharmacy in older people found
that the quality of available evidence was low, owing to
risk of bias in the included studies. In addition, details of
intervention development and delivery were lacking in
published reports [14]. This prevents researchers and cli-
nicians from understanding how the interventions were
intended to exert their effects and limits the potential
for effective interventions to be replicated and optimised
in clinical practice. Accordingly, a more systematic ap-
proach, incorporating both evidence and theory, was rec-
ommended for the development of future interventions
[14]. This is in line with the UK Medical Research Coun-
cil’s (MRC) complex intervention framework, which rec-
ommends that intervention development be guided by
best available evidence and appropriate theory [15]. It is
recommended that after the intervention is developed,
preliminary evaluations in the form of feasibility and pilot
studies be conducted to estimate parameters (e.g. recruit-
ment/retention rates, sample size) that are important for a
full-scale clinical trial.
As part of a multiphase mixed methods research pro-
ject, an intervention-targeting general practitioners
(GPs) was developed to improve the prescribing of ap-
propriate polypharmacy for older people (outlined
below). Full details of the preliminary work underpin-
ning the intervention’s development are reported in two
related papers [16, 17]. Briefly, the intervention develop-
ment process followed a systematic approach based on
the MRC framework by incorporating evidence and the-
ory [15]. A Cochrane systematic review was updated to
establish the existing evidence base [14]. Qualitative in-
terviews that were underpinned by a theoretical frame-
work of behaviour change (i.e. Theoretical Domains
Framework (TDF) [18]) were conducted with GPs. The
TDF-based interviews provided a method for identifying
theoretical domains that were perceived as barriers and
facilitators to the prescribing of appropriate polyphar-
macy for older people [16]. These theoretical domains
were then mapped to behaviour change techniques
(BCTs) from an established taxonomy [19] and embed-
ded in the intervention as the proposed ‘active ingredi-
ents’ [17]. Hence, a theory base was incorporated into
the intervention development process, as advocated by
the MRC framework [15].
This study sought to test the feasibility of this inter-
vention, which targeted GPs to improve the prescribing
of appropriate polypharmacy for older people in primary
care. This involved assessing the intervention’s usability
and acceptability to determine if the intervention’s
content and delivery required further refinement.
Recruitment methods, data collection procedures and the
selection of assessment measures were also examined to
determine if the study protocol required further refine-
ment before progressing to a randomised pilot study.
Methods
This feasibility study was conducted in two general
practices. Ethical approval was granted by the Office of
Research Ethics Committees Northern Ireland in advance
of the study (REC reference 15/NI/0104). The study is
registered with the ISRCTN registry (ISRCTN18176245).
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Aim and objectives
The primary aim of the study was to assess the feasibility
of a GP-targeted intervention to improve the prescribing
of appropriate polypharmacy for older people in primary
care. This aim was met through the study objectives,
which were to:
1. Evaluate the methods of participant recruitment
2. Assess the intervention’s usability and acceptability
(to GPs and patients)
3. Assess the fidelity of delivery of pre-specified behaviour
change techniques that were embedded in the
intervention
4. Evaluate data collection procedures (including the
utility of selected assessment measures/tools)
Sampling and recruitment
A convenience sampling method was used to recruit
GPs from two general practices (one urban and one
rural) into the study. Practices were sampled from nine
general practices that had participated in the earlier
qualitative interview phase of the project (see Cadogan
et al. [16]). The main reason for approaching these prac-
tices initially was because they had participated in the
earlier phase of the study during which the intervention
had been developed to target specific theoretical do-
mains that were reported to be affecting the prescribing
of appropriate polypharmacy by GPs within these prac-
tices. Therefore, these GPs were considered to be best
placed to test the usability and acceptability of the inter-
vention in addressing the specific challenges that they
(and/or their colleagues) reportedly faced in clinical
practice.
The researcher (CC) approached two practices and in-
vited GPs within the practice to participate in the feasi-
bility study. General practices were contacted until two
practices had agreed to hold a meeting with the re-
searcher with a view to participating in the study. At
these meetings, the researcher provided GPs with an
overview of the feasibility study and intervention (described
below), as well as a study folder containing all relevant
study documentation (i.e. participant information leaflets,
consent forms, written instructions and login details for
accessing the intervention’s online video component (de-
scribed below). A maximum of five GP participants were
sought per practice so that the study workload could be
divided evenly across GPs within recruited practices (i.e.
each GP would engage with one patient participant as part
of the study).
Each participating general practice recruited five older
patients meeting inclusion criteria (i.e. over the age of
65, receiving four or more regular medicines, not cogni-
tively impaired, resident in the community) into the
study. Nursing home residents were excluded from the
study as their clinical complexity and context is very dif-
ferent to community-dwelling patients. Patient recruit-
ment was facilitated by nurses from the Northern
Ireland Clinical Research Network (NICRN) who
screened practice records and issued written invitation
letters and study information sheets to patients meeting
inclusion criteria. GPs reviewed the final list of identified
patients before invitation letters were issued to ensure
that patients met the inclusion criteria and were suitable
for review. The invitation letters asked patients to con-
tact the practice if they were interested in having a con-
sultation with their GP about their medicines on a
specified date (practice 1: August 2015, practice 2: Sep-
tember 2015). GPs agreed to accommodate any patients
who were interested in booking a consultation but were
not able to attend the practice on the specified date.
However, these patients were not recruited into the
study. Invitation letters were issued in batches and the
number of letters issued in the first round was agreed
between the NICRN nurses and the participating GPs in
order to ensure that the practice could accommodate
patients if uptake was higher than anticipated. This re-
sulted in an initial batch of 20 and 15 invitation letters
being issued from practices 1 and 2, respectively. The
patient sampling quota was reached in each practice
after the first batch of invitation letters was issued.
The researcher obtained written informed consent
from all GP and patient participants prior to consulta-
tions taking place. Each general practice was offered fi-
nancial compensation (£500) for the time and resources
associated with study participation. GP participants were
provided with a certificate of participation for their con-
tinuing professional development portfolios. No incen-
tive was offered to patient participants.
Intervention content and delivery
The intervention consisted of a short online video (ap-
proximately 11.5 min) that was delivered to GPs and
demonstrated how GPs prescribe appropriate polyphar-
macy during a typical consultation with an older patient
(BCT: ‘Modelling or demonstrating of behaviour’—as
defined according to BCT Taxonomy Version 1 [19]).
The video was scripted by the research team, and the
clinical content was developed by an academic GP and
geriatrician with input from pharmacists. The video
included feedback from both a practising GP and a
simulated patient emphasising the positive outcomes of
the consultation (BCT: ‘Salience of consequences’—as
defined according to BCT Taxonomy Version 1 [19]). A
professional video production team was commissioned
to record the video which was delivered to GP partici-
pants online. The video was uploaded onto a secure web
server using the ‘Riverside®’ software programme and
accessed by GPs using a generic username and
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password. Written instructions and login details to ac-
cess the video were included in the study folder that
each practice received from the researcher. Patient par-
ticipants were not provided with access to the video.
As a complementary intervention component, patients
were invited to scheduled medication review consulta-
tions with GPs. Explicit plans were made at weekly
meetings with practice staff (i.e. GPs, practice nurses, re-
ception staff ) of when and how GPs would ensure that
target patients were prescribed appropriate polyphar-
macy (BCT: ‘Action planning’—as defined according to
BCT Taxonomy Version 1 [19]). GPs had oversight of
the patients who were being invited to participate in the
study and allocated time slots in their weekly schedule
to conduct review consultations with patients as part of
the study. Reception staff scheduled the consultations
for patients who responded to the invitation letter and
prompted GPs to carry out the agreed plan to review
target patients’ medications when they presented at the
practice by notifying participating GPs that the patients
were attending a scheduled consultation as part of the
study (BCT: ‘Prompts/cues’—as defined according to
BCT Taxonomy Version 1 [19]).
Specification of intervention content using BCTs
A BCT coding exercise was conducted by way of a
fidelity check in order to investigate if the pre-
specified BCTs (i.e. ‘Modelling or demonstrating of
behaviour’, ‘Salience of consequences’) embedded in
the video were readily identifiable to an independent
group of researchers. This was intended to add to
the methodological rigour of the intervention devel-
opment process that has previously been described
(see Cadogan et al. [17]).
The video coding exercise was performed by an inde-
pendent group of seven researchers who had previously
undergone standardised training in BCT coding (through
either tutorials or an online course). Coders had no prior
involvement in the project. The group was shown the
video, and each member was provided with a transcript
of the video (i.e. the script that was used by the actors
and descriptive details of each scene). Each coder inde-
pendently coded the video content by assigning BCTs
from the published BCT taxonomy [19] to sections of
the video transcript. Coders also reported ratings of their
confidence in each coding judgement using a rating scale
from the standardised BCT training programme (‘+’ =
fairly confident; ‘++’ = extremely confident) [20]. Coders
were instructed to code sections of the video transcript
to any given BCT once only, even if the particular BCT
was deemed to have been delivered multiple times. A
BCT was deemed to have been embedded in the video
where the majority of coders (≥4) had assigned the BCT
to sections of the video transcript.
Outcomes
The primary feasibility outcomes were the usability and
acceptability of the intervention to GPs. Feedback from
patients regarding the acceptability of the medication re-
view with their GP was also included in the overall
evaluation.
As secondary feasibility outcomes, study parameters
were investigated that would ultimately help to inform
the design of a future pilot study (i.e. recruitment, data
collection procedures). For example, the study assessed
the feasibility of collecting feedback from GPs and pa-
tients using self-administered questionnaires that were
to be completed in a hard copy form and returned using
postage-paid envelopes. The study also assessed the
feasibility of applying validated assessment tools to the
patients’ medical record data, as well as the utility of se-
lected assessment tools.
Data collection and analysis
In assessing the feasibility study outcomes, data were
collected from GPs, patients and practice records as de-
scribed below.
Feedback from GP and patient participants
Recruited GPs were asked to complete a structured
paper-based questionnaire (Additional file 1) after they
had watched the online video and performed medication
reviews with recruited patients. The questionnaire
assessed the intervention’s usability and acceptability.
We were unable to identify any previously validated tool
that would be directly applicable to the assessment of
our intervention. We had originally intended to include
the System Usability Scale (SUS) in the GP feedback
questionnaire [21]. SUS is a simple 10-item scale de-
signed to provide a subjective assessment of a system’s
usability. However, as the scale’s questions related more
specifically to the video’s online mode of delivery as op-
posed to its content, it was not considered to be an ap-
propriate tool for the purpose of the current feasibility
study. Instead, we adapted items that were included in
the GP feedback questionnaire of the online video (i.e. a
form of technology) from Davis’ Perceived Usefulness
Scale [22]. This scale forms part of the Technology Ac-
ceptance Model (TAM) which was developed to explain
technology usage behaviour [22].
Feedback was gathered under three main subheadings:
‘Video use and usefulness’, ‘Online system for accessing
video’ and ‘Medication review process’ (Table 1). Add-
itional questions were included to investigate whether
GPs would recommend any changes to the video or online
delivery system for future studies. The questionnaire
included fixed category response options and 5-point Likert
scales. Free-text response options were also provided to
allow respondents to elaborate on their responses.
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Recruited patients were asked to complete a feedback
questionnaire (Additional file 2) after the consultation
with their GP. The questionnaire examined patients’
views and experiences of the medication review process
under two main subheadings: ‘medication reviews with
the GP’ and ‘the scheduled consultation’. The question-
naire included the same types of response options as the
GP questionnaire.
All questionnaires were completed in hard copy form
and returned to the researcher (CC) using a pre-paid
postage envelope labelled with the researcher’s work ad-
dress. Questionnaire data were analysed using IBM SPSS
Statistics v.21. Simple descriptive analyses were con-
ducted to summarise the data. Content analysis was
performed on free-text questionnaire responses for gen-
eration of representative themes. Each of the answers to
the open-ended questions was reviewed separately, and
key subthemes relating to the answers were identified by
the researcher (CC). A summary document that
included all free-text responses and an overview of the
content analysis was presented to other members of the
research team for discussion. There were no disagree-
ments with the presented results.
Practice record data
Clinical data were extracted from recruited patients’
medical records by research nurses from the NICRN at
baseline (date of scheduled consultation) and at follow-up
(1 month post-consultation). Extracted data consisted of
patients’ demographics (i.e. age, gender), clinical condi-
tions and prescribed medications (acute list and repeat list
items). Validated assessments of prescribing appropriate-
ness (i.e. Screening Tool of Older People’s potentially
inappropriate Prescriptions (STOPP)/Screening Tool to
Alert doctors to Right Treatment (START) criteria [23],
Medication Appropriateness Index (MAI) [24]) and
prescribing regimen complexity (i.e. Medication Regimen
Complexity Index (MRCI) [25]) were applied to the
extracted clinical data.
As there is currently no ‘core outcome set’ (i.e. an
agreed or standardised set of outcomes that should
be assessed and reported as a minimum) for trial
evaluations of interventions aimed at improving ap-
propriate polypharmacy [26], each assessment tool
was purposefully selected by the research team.
Firstly, due to the lack of a validated measure of ap-
propriate polypharmacy, we used validated general
measures of prescribing appropriateness as surrogate
measures. Specifically, an implicit (judgement-based)
tool and an explicit (criterion-based) tool were used
(i.e. MAI [24] and STOPP/START criteria [23], re-
spectively). This combination of tools was intended to
help overcome inherent limitations of each assess-
ment tool, details of which have been documented ex-
tensively in the literature (see Kaufman et al. [27] for
a detailed overview of available prescribing tools).
Assessments of prescribing appropriateness using the
MAI [24] involve applying a score to each medica-
tion, and a total MAI score per person is then re-
ported by adding the scores for individual
medications. Using this approach, the possible range
of scores is 3 (more appropriate) to 18 (less appropri-
ate) for each prescribed medication. Assessments of
prescribing appropriateness involving STOPP/START
criteria [23] report the prevalence of each criterion
within the sample population. These criteria consist
of 80 STOPP criteria and 34 START criteria.
We also sought to evaluate additional factors (e.g.
dosage forms, dosing frequencies), other than the
number of medicines prescribed, that contribute to the
overall complexity of drug regimens using the MRCI
[25]. This tool involves assigning a score to quantify
complexity of medication regimens based on the pre-
scribed dosage forms, dosing frequencies and additional
directions. Each assessment tool was applied by two
members of the research team working independently
(CC, CR). Any disagreements were resolved by consen-
sus discussion and consultation with a third member of
the research team (CH).
Table 1 Sample questionnaire items
Questionnaire
section
Questionnaire item
Video use and usefulness Using videos like this would make it easier for me to perform medication reviews with older
patients in daily practice.
Using videos like this would increase the number of medication reviews that I perform with older
patients in daily practice.
Online system for accessing video Did you experience any problems using the online system? (If yes, please briefly outline)
If the online system was to be further developed as a resource to assist GPs in prescribing
appropriate polypharmacy for older people, what types of additional material and/or resources
would you like to see included?
Medication review process Think back to a medication review that you performed with an older patient as part of this study.
Did you make any changes to the patient’s prescription?
If yes, was there anything that made it difficult for you in putting this change(s) into effect?
(please briefly outline)
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Results
Participant recruitment
Each of the first two general practices that were con-
tacted about the study agreed to take part in the feasibil-
ity study. Four GPs (3 female, 1 male) were recruited
into the study from these practices (practice 1: three
GPs; practice 2: one GP). Patients who received an invi-
tation letter and were interested in attending the prac-
tice to have a consultation with their GP about their
medicines on the specified date contacted the practice.
Each practice scheduled consultations between GP par-
ticipants and five older patients who were receiving
polypharmacy.
Each patient attended the practice for a scheduled con-
sultation and was recruited into the study (total sample
size of 10 patients; five per practice). Six of the ten patient
participants were female (Table 2). Participants’ median
age was 73.5 years (range 68–78 years). All patient partici-
pants were multimorbid (median number of chronic
conditions: 3) and were receiving at least four regular
medicines (median number of medicines: 6) at baseline.
GP feedback
Responses to the feedback questionnaire were received
from both participating practices, with three of the four
GP participants returning completed questionnaires. All
of the questionnaire respondents were female. The num-
ber of years respondents had been practising as GPs var-
ied (range 9–20 years).
Video use and usefulness
Each GP reported watching the online video (primary
intervention component) at least once prior to the first
patient consultation that was scheduled as part of the
study (one GP reported watching the video once and
two GPs reported watching the video twice). The re-
spondents’ views on the perceived usefulness of the
video varied (Table 3). The respondents were undecided
(2 neutral, 1 agree) as to whether the video would make
it easier for them to perform medication reviews with
older patients in daily practice.
The respondents reported that the videos would im-
prove their performance of medication reviews with
older patients (2 agree, 1 disagree), enhance their effect-
iveness in implementing prescribing changes (2 agree, 1
neutral) and increase the total number of medication
reviews that they performed in daily practice (1 strongly
agree, 1 agree, 1 neutral). Respondents reported mixed
views about whether videos would help them to review
older patients’ medications more quickly in daily prac-
tice (1 strongly disagree, 1 disagree, 1 agree).
In answer to the questions with free response format,
respondents commented that as a resource intended to
help GPs to prescribe appropriate polypharmacy for
older patients, they liked that the video was short, realis-
tic and based on a practical scenario that they would
encounter in daily practice.
Practical; scenario taken from ‘daily practice’; short
(study site, 1 GP2).
….short but effective, realistic (study site 2, GP1).
One respondent found it particularly helpful that the
video included a monologue in which the GP outlined
the underlying rationale for proposing changes to the
patient’s prescription, as well as a plan for implementing
the changes.
Two respondents described issues that would nega-
tively impact on the usefulness of the video as a
resource. One commented that the video ‘…even well
done like this, simplifies what is a very complex inter-
action in practice’. The other respondent noted that time
was often lacking to arrange structured consultations
with patients to review their medications.
One respondent recommended a change to the video
for future studies: the inclusion of an explicit summary
of the recommended prescribing changes using re-
sources such as NO TEARS [28] (a tool for conducting
medication reviews) or STOPP/START [23] (validated
criteria for assessing the appropriateness of prescribing
in older people).
All three respondents stated that they would recom-
mend the video to a colleague as a resource to assist the
prescribing of appropriate polypharmacy for older
people. One GP commented that the video created
awareness of the importance of reviewing older patients’
Table 2 Summary statistics of patient demographics
Gender
Male 4
Female 6
Age (years)
Mean (±standard deviation) 73.1 (±4.04)
Median 73.5
Range 68–78
Number of repeat medications
Mean (±standard deviation) 6.4 (±2.2)
Median 6
Range 4–10
Number of chronic conditionsa
Mean (±standard deviation) 3.4 (±1.4)
Median 3
Range 2–7
aAssessment based on clinical conditions recorded in patients’ medical records
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medications to ensure that they are prescribed appropri-
ate polypharmacy and would encourage her to do so
more frequently in practice.
Highlights importance; creates awareness and I feel I
will do it more frequently (study site 1, GP2).
However, another respondent noted that colleagues
‘may also feel that it doesn’t reflect ‘real-life’ with the
usual time pressure we work under’ (study site 2, GP1).
Online system for accessing video
None of the GP respondents encountered any problems
in using the online system to access the video.
GPs listed a number of additional prescribing-related re-
sources that they would like to see included if the online sys-
tem was to be further developed. These resources included
a STOPP/START toolkit; printable patient information leaf-
lets (PILs) for use in medication reviews with space for pa-
tients to write questions/problems that they could then
discuss with their GPs at the next visit; patient decision aids
for common conditions; and information on medication er-
rors and interactions associated with polypharmacy in older
people. One GP stated that an online forum to discuss pre-
scribing issues with peers/pharmacists would be useful.
Medication review process
When asked to reflect on the last patient that they had
reviewed as part of the study, all GP respondents re-
ported making changes to the patients’ prescriptions. All
prescribing changes involved the reduction or discon-
tinuation of medications. The medications that were
reportedly changed consisted of analgesics (unspecified),
a proton pump inhibitor (lansoprazole), a H2-receptor
antagonist (ranitidine), an antacid, a leukotriene antag-
onist (montelukast), an antihypertensive (olmesartan)
and a diuretic (bendroflumethiazide).
Two GP respondents outlined issues that created diffi-
culties in putting the reported prescribing changes into
effect. For one GP, time was a barrier to implementing the
prescribing changes. The other GP reported that the pa-
tient was receiving an excessive dose of a medication that
was being prescribed for an unlicensed indication which
was further complicated by the fact that it had been previ-
ously been initiated by another GP many years ago.
GP respondents outlined a range of issues that facili-
tated them in implementing the prescribing changes. All
of the respondents commented on aspects of the inter-
vention (i.e. allocated consultation time, patient engage-
ment, consultation style of GP in the video) that
facilitated the prescribing of appropriate polypharmacy.
One GP also referred to concerns for patient safety and
the medico-legal implications of not taking action to en-
sure that patients were prescribed appropriate
polypharmacy.
GP respondents expressed a preference for conducting
medication reviews with older patients either using
scheduled consultations (n = 2) or on an ad hoc/oppor-
tunistic basis (n = 1). All of the respondents reported
that having protected time would encourage them to
perform medication reviews with older patients who are
receiving polypharmacy. GP respondents listed a range
of clinical issues that would also encourage them to per-
form medication reviews with this cohort of patients
(e.g. presence of complex co-morbidities, specialist
drugs, side effects). One GP commented on the need for
appropriate resources in order to conduct medication
reviews with these patients in practice, such as chronic
disease management clinics and support from peers/
community pharmacists.
Patient feedback
All ten patient participants returned completed feedback
questionnaires (response rate 100%).
Patients’ views on medication reviews with GPs
Most participants indicated that they would like their
medication to be reviewed by their GP either once every
Table 3 GP respondents’ views on the perceived usefulness of the video (n = 3)
Using videos like this would… Strongly disagree Disagree Neutral Agree Strongly agree
…make it easier for me to perform medication
reviews with older patients in daily practice.
2 1
…improve my performance of medication
reviews with older patients in daily practice.
1 2
…enhance my effectiveness in implementing
prescribing changes during medication reviews
with older patients.
1 2
…help me to complete medication reviews with
older patients more quickly in daily practice.
1 1 1
…increase the number of medication reviews that
I perform with older patients in daily practice.
1 1 1
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6 months (n = 4) or once every 12 months (n = 5). One
participant stated that he wished for his medication to
be reviewed by his GP every time he ordered a repeat
prescription.
All participants reported that it was important to have
a face-to-face consultation with their GP when having
their medications reviewed.
I think it is important to review the medication and
side-effects. I would find this more effective in a face-
to face-appointment. Also the GP could assess the
present health. Study site 2, patient 2
You can ask any questions about your medication
which are bothering you and get an immediate answer
with a qualified doctor. Study site 2, patient 3
…it is important to feel involved with your care. Study
site 2, patient 4
Patient feedback on the scheduled consultation
The main outcome that patients expected from the con-
sultation was that they would find out whether their
current treatment regimens required any changes. Seven
of the patients reported that the GPs recommended
changes to their current prescriptions during the sched-
uled consultations. These patients agreed with the rec-
ommended changes, most of which involved the
reduction or discontinuation of existing medications.
The patients also stated their satisfaction with the
consultation. Patients welcomed the opportunity to have
their medications reviewed by their GP.
I found the medication review very useful and most
reassuring, as I have often wondered if all of the
medication I was taking a few years ago was really
necessary. Study site 2, patient 3
This was an important exercise. I now realise that
without a regular review, people like me and countless
others could still be taking medication they were
prescribed years ago and have become ineffective….
Study site 1, patient 4
I welcomed the opportunity to discuss medication
with GP as I had some worries and needed
reassurance. I found the interview very satisfactory.
Study site 2, patient 2
Supplementary video coding exercise
The results of the video coding exercise are shown in
Table 4. The coders agreed that the video contained
‘Modelling or demonstration of the behaviour’ as a pre-
specified BCT, as well as another related BCT (‘Instruc-
tion on how to perform the behaviour’). The coders
identified additional BCTs relating to the consequences
of performing the behaviour (‘Information about health
consequences’, ‘Information about social and environ-
mental consequences’), in place of the pre-specified BCT
(‘Salience of consequences’) and ‘Credible source’ as an
additional BCT that had not been pre-specified by the
research team.
Clinical record data
It was not feasible to apply the validated assessments of
prescribing appropriateness (i.e. STOPP/START criteria
[23], MAI [24]) to the extracted clinical data. This was
because the level of detail regarding patients’ current
clinical diagnoses and treatment durations in the
extracted data was insufficient to determine whether
Table 4 Outcomes of independent video coding exercise using BCT taxonomy [19]
Behaviour change techniques embedded within online video BCTs pre-specified by research team BCT identified by video coding team
Modelling or demonstration of the behaviour (provide an
observable sample of the performance of the behaviour,
directly in person or indirectly, e.g. via film or pictures
for the person to aspire to or imitate)
X X
Credible source (present verbal or visual communication
from a credible source in favour of or against the behaviour)
X
Information about health consequences (provide information,
e.g. written, verbal, visual, about health consequences of
performing the behaviour)
X
Instruction on how to perform the behaviour (advise or
agree on how to perform the behaviour)
X
Information about social and environmental consequences
(provide information, e.g. written, verbal, visual, about
social and environmental consequences of performing
the behaviour)
X
Salience of consequences (use methods specifically
designed to emphasise the consequences of performing
the behaviour with the aim of making them more
memorable—goes beyond informing about consequences)
X
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patients’ clinical indications were being treated appropri-
ately, according to the tools. Similarly, it was also not
possible to conduct a complete assessment of prescrib-
ing regimen complexity using the MRCI [25] as details
of additional directions for each prescribed medication
were not available from patients’ medical records.
It was also not possible to verify whether any of the
prescribing changes reported in the feedback question-
naires had been implemented (according to the patient
case notes) as the 1 month timeline between baseline
and follow-up was insufficient to detect any changes in
the prescriptions that were issued to patients.
Discussion
This study assessed the feasibility of an intervention to
improve the prescribing of appropriate polypharmacy for
older people in primary care. The study forms part of a
systematic process of intervention development and
evaluation that models the MRC framework [15]. In this
way, the study serves to address limitations of previous
related intervention studies whereby details of interven-
tion development and preliminary evaluation (i.e. feasi-
bility/pilot testing) were lacking [14].
Intervention usability and acceptability
In assessing the primary feasibility outcomes, the feed-
back received from recruited GPs showed that the inter-
vention was deemed to be both usable and acceptable
for improving the prescribing of appropriate polyphar-
macy for older people in primary care. For example, GPs
expressed largely positive views regarding the video’s
content and its impact on their prescribing behaviour
(i.e. increased number of medication reviews performed
in daily practice, enhanced effectiveness in implementing
prescribing changes). However, some reservations were
expressed as to whether the clinical scenario depicted in
the video truly reflected ‘real-life’ and the ‘usual time
pressures’ encountered in the general practice work
environment.
As detailed in our earlier intervention development
work [16, 17], we recognised that the current work envir-
onment (i.e. time and resource limitations) was a major
barrier to the target behaviour (i.e. prescribing of appro-
priate polypharmacy), and therefore, we purposefully
sought to develop an intervention that would limit any
additional workload for GPs in prescribing appropriate
polypharmacy. The video demonstration was intended to
highlight to GPs how they could potentially incorporate
reviews of older patients’ medications into routine clinical
practice and use available time more efficiently. Thus, the
intervention was intended as a strategy for introducing
small changes into GPs’ current prescribing behaviour
within the constraints of the existing work environment
with a view to building on these changes over time. As
noted by Michie et al., ‘introducing change incrementally
and building on small successes can be more effective
than trying to do too much too quickly’ [29].
The scheduled consultations that formed part of the
intervention approach served an important function. As
noted by GP participants, protected time was an import-
ant facilitator in reviewing patients’ medications. The
scheduled consultations were also endorsed by the posi-
tive feedback received from recruited patients. Patients
valued the opportunity to have their medications
reviewed by their GP. If the intervention is found to be
effective in a future trial evaluation that is currently be-
ing developed, this component of the intervention could
help contribute to the reorganisation of care required
for implementing best practice guideline recommenda-
tions for patients with multimorbidity who typically re-
quire multiple medication (polypharmacy) [12]. Further
refinement of the intervention for this future evaluation
will involve incorporating GP participants’ suggestions to
incorporate additional prescribing-related support ma-
terial (e.g. validated screening tools for identifying po-
tentially inappropriate prescribing in older people) into
the online system that was used to access the video.
The study was also designed to test the feasibility of
the study procedures (e.g. participant recruitment, data
collection/analysis). The GP and patient recruitment
strategies proved feasible whereby the sampling targets
of two general practices and five older patients per
practice were reached. In scaling up the number of
participating general practices for future evaluations of
the intervention, it will be important to engage with key
stakeholders, such as GP representatives, to ensure that
an appropriate level of remuneration can be offered to
general practices for the time allocated to study partici-
pation. This will be dependent on the number of pa-
tients to be recruited and the number of follow-up
assessments to be conducted.
Data collection procedures
The procedures for collecting feedback from GP and pa-
tient participants were largely successful, with only one
non-respondent. However, the study highlighted import-
ant limitations with the clinical data that were collected,
whereby we were unable to assess patients’ clinical data
using each of the validated assessment tools. We were
also unable to detect any prescribing changes due to the
length of the follow-up assessment (1 month post-
consultation). Future evaluations of the intervention will
look to include a series of follow-up assessments at six
monthly intervals for a minimum of 1 year post-
intervention. An assessment period with multiple assess-
ment points will help to detect if prescribing changes are
implemented and subsequently sustained. In addition, a
full clinical review by a trained research pharmacist may
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also need to be conducted with recruited patients at base-
line and follow-up. This should help to ensure that suffi-
cient clinical information is available to allow the
validated assessment tools of prescribing appropriateness
to be applied (i.e. STOPP/START criteria [23], MAI [24]).
The clinical review could then be coupled with pharmacy
dispensing data in order to ensure that sufficiently detailed
information is collected regarding medication instructions
in order to allow the MRCI to be applied properly [25].
Challenges and limitations
Despite the small-scale nature of the current feasibility
study and the relatively low number of GP participants
(n = 4), designing the study protocol posed a number of
challenges. Firstly, there has, to date, been a lack of con-
sensus in the literature as to the distinction between the
terms ‘pilot study’ and ‘feasibility study’ [30, 31]. Conse-
quently, the two terms have often been used inter-
changeably. A recently published conceptual framework
for defining feasibility and pilot studies in preparation
for randomised controlled trials will help to clarify how
the terms should be applied in future research [32].
However, for the purpose of the current study, we had
adopted the definition that is used by the National Insti-
tute of Health Research (NIHR) Evaluation, Trials and
Studies Coordinating Centre (NETSCC) in the UK
which defines feasibility studies as pieces of research that
are carried out before the main study in order to esti-
mate important parameters that are needed to design
the main study and to determine whether the study can
be done [33]. Hence, the study findings relating to par-
ticipant recruitment and data collection procedures were
more important than verifying whether reported pre-
scribing changes had been implemented.
In collecting feedback from GP and patient partici-
pants, we chose a questionnaire-based format because
time and resource limitations did not permit an in-depth
follow-up study using qualitative methods (e.g. semi-
structured interviews). The questionnaires included a
number of free-text response options in order to allow
participants to provide detailed responses. However, the
availability of validated tools for constructing question-
naire items to assess the primary feasibility study
outcomes (i.e. usability and acceptability) proved chal-
lenging. Therefore, items included in the GP feedback
questionnaire of the online video were adapted from
Davis’ Perceived Usefulness Scale [22]. Perceived useful-
ness and perceived ease of use are two constructs that
form part of the TAM [22]. Empirical research indicates
that the TAM is a good predictor of physicians’ behav-
ioural intention to accept technology [34]. As a con-
struct, perceived usefulness has been found to directly
influence physicians’ intention to accept technology [34].
We did not include questionnaire items to measure
perceived ease of use as we did not feel that the ques-
tions could be meaningfully applied to the evaluation of
the online video intervention (e.g. ‘Learning to operate
the online video would be easy for me.’, ‘I would find it
easy to get the online video to do what I want it to do.’).
In addition, there have been suggestions that the con-
struct’s importance to the model may be reduced in tar-
get groups with a high level of competency, such as
physicians [35]. Although caution has been urged in
using the TAM as a predictor of technology usage out-
side the context in which it has been validated [36], we
did not intend to make predictions based on the re-
sponses to the feedback questionnaire. The adapted
questionnaire items (Tables 1 and 3) that were included
in our feedback questionnaire were intended to form
part of our overall assessment of the intervention’s us-
ability and acceptability to GPs and to determine if the
intervention content required additional refinement be-
fore undergoing further evaluation.
Finally, in assessing the intervention, we focussed on
process measures of prescribing appropriateness using
validated assessments (i.e. STOPP/START [23], MAI
[24]). It must be noted that appropriate polypharmacy is
an ideal concept as opposed to a fixed end-point and the
threshold that differentiates between the prescribing of
‘many’ drugs and ‘too many’ drugs will vary according to
an individual patient’s existing clinical conditions and life
expectancy [26]. In the absence of a validated measure
of appropriate polypharmacy, validated general measures
of prescribing appropriateness (e.g. MAI [24], STOPP/
START criteria [23]) will continue to play an important
role as surrogate measures in evaluations of interven-
tions seeking to improve prescribing for older people. In
progressing to a future pilot study, it will be important
to include clinical outcome measures (e.g. hospital
admissions), as well as process measures. Members of
the research team are currently involved in the develop-
ment of a core outcome set (COS) for use in interven-
tions aimed at improving appropriate polypharmacy in
older people in primary care (http://www.comet-initiative.org/
studies/details/933). This work will help in selecting the most
appropriate clinical outcome measures to include in
any future pilot study of the intervention.
Specification of intervention content using BCTs
In addition to the value of the feasibility study find-
ings, the BCT coding exercise was an important
methodological step as it showed that the video inter-
vention may have included additional BCTs to those
that were specified a priori. There are a number of
possible explanations to account for this finding.
Firstly, the availability of formal training courses in
BCT coding is a relatively recent development. It is
important to note that although the BCT coders had
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undergone previous training in BCT coding, the train-
ing content was standardised but the delivery format
varied (e.g. tutorials, online course). A number of pre-
vious BCT training courses have focused on specific
subsets of BCTs (e.g. most frequently occurring BCTs)
due to the practicalities involved in providing inten-
sive training that covers all 93 BCTs within the
current taxonomy [20]. Hence, our coders may not
have been familiar with all of the BCTs that we had
included in our intervention (e.g. ‘Salience of conse-
quences’). Furthermore, if the coders had been specif-
ically trained in identifying a subset of BCTs, this
could have potentially resulted in a form of recall
bias.
Secondly, it has been proposed that further clarifica-
tion of particular BCT definitions may be required in
order to improve the reliability of BCT coding [37]. A
number of BCTs that were identified by the coders (e.g.
‘Information about health consequences’, ‘Information
about social and environmental consequences’, ‘Demon-
stration of the behaviour’, ‘Instruction on how to perform
the behaviour’, ‘Credible source’) have previously pre-
sented problems for other trained BCT coders with im-
plications in terms of coding reliability (i.e. inter-rater
and test-retest reliability) [37]. Based on the current
findings, it is clear that in order for independent coding
to perform a valid and reliable fidelity check on an inter-
vention’s component BCTs, coders will need to have pre-
viously undergone a valid, effective and standardised
training programme.
Conclusion
A GP-targeted intervention that aimed to improve the
prescribing of appropriate polypharmacy for older
people in primary care that was previously developed
using a systematic, theory-based approach has now
undergone feasibility testing. The feasibility study find-
ings show that the intervention was both usable and
acceptable to GPs in improving the prescribing of appro-
priate polypharmacy for older people. Further refine-
ments to the intervention will involve incorporating
additional prescribing-related support material into the
online system through which GP participants accessed
the video. The feasibility study also helped to identify
important limitations with the data collection proce-
dures. Additional clinical information regarding patients’
existing conditions and the instructions they receive as
to how to take their medications correctly will be re-
quired in future evaluations in order to apply validated
assessment tools of prescribing appropriateness and
medication regimen complexity. An additional prelimin-
ary evaluation of the intervention using a randomised
pilot study is currently being developed. This will help
in designing a definitive randomised trial to investigate
the effectiveness of the intervention at improving appro-
priate polypharmacy for older people in primary care.
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